TxCell launches new manufacturing process development laboratories

French biotech firm TxCell (Euronext Paris: TXCL) has announced the launch of its new process industrialization laboratories and technology transfer academy facilities in Sophia Antipolis, France.

These new facilities will be primarily dedicated to the improvement of the existing TxCell manufacturing process for its ASTrIA platform as well as to the development of a manufacturing process for its new ENTrIA platform. These developments will be primarily achieved by combining the integration into the manufacturing process of findings from TxCell research with industry advancements in the life science and technology industries. The outcome will be an increase in automation and economic efficiencies as well as a shortening of the manufacturing process of all TxCell products across all of its platforms.

“TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). As a result, TxCell is integrating its own research with recent technological advancements across a variety of fields to make the manufacturing process of our product portfolio as economic as possible,” said Miguel Forte, chief operating officer of TxCell, adding: “The new TxCell facilities will be dedicated to accelerating the development of the commercial manufacturing process for products that result from the TxCell ASTrIA platform. In addition, it will allow the development of a new manufacturing process for products derived from the new TxCell ENTrIA platform.”